血清Vaspin Endocan在不稳定型心绞痛合并高血压病的表达及其临床意义

doi:10.3969/j.issn.1006-6233.2019.02.019

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (1570 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression and clinical meaning of visceral adipose tissue-derived serine protease inhibitor(Vaspin) and endothelial cell specific molecule-1(Endocan) in patients with unstable angina combined with hypertension. Methods: Our research included in 4 groups:43 patients with hypertension for HD group,61 patients with unstable angina for UA group,90 patients with unstable angina combined with hypertension for UA with HD group,35 healthy peaple for control group,All patients were diagnosed and treated in our hospital from 2017-02 to 2018-02.Vaspin and Endocan were detected by ELISA. Results: Compared with control group,Vaspin and Endocan level in HD,UA and UA with HD groups were statistically significant difference(P<0.05),and Vaspin level gradually declined while Endocan increased.Pearson correlation analysis showed that the level of Vaspin was negatively correlated with the number of coronary lesions and the Gensini score(P<0.05), while Endocan positively correlated with the number of coronary lesions and the Gensini score(P<0.05),Vaspin and Endocan were negatively correlated(r=-0.715,P<0.05).ROC curve analysis showed that the area under curve of UA with HD and HD groups with Vaspin and Endocan were 0.877、0.850,respectively(P<0.05), and the UA with HD and UA groups were 0.692、0.689,respectively(P<0.05).Conclusion: Vaspin and Endocan were related to the severity of cardiovascular disease and could be used for predicting the early prognosis in unstable angina combined with hypertension.

Key words： Vaspin Endocan Unstable angina Hypertension

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.02.019 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I2/245

[1] Motawi TK, Mahdy SG, Maha M. El-Sawalhi,et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis[J]. Can Physiol Pharmacol,2017,96: 38~44.
[2] Tariket S, Sut C, Arthaud CA, et al. Modeling the effect of platelet concentrate supernatants on endothelial cells: focus onendocan/ESM-1[J].Transfusion, 2017.
[3] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].Chin Cardiol, 2017, 45(5): 359~376.
[4] Tony Stanton, MBChB, PhD, et al.Hypertension, Left Ventricular Hypertrophy, and Myocardial Ischemia[J]. 2017,29~41.
[5] Wang LQ,Sun LM,Wang YL,et al.The effect of rosuvastain and atorvastain on serum adipokine Vaspin in patients with coronary heart disease[J].Pract Med,2015,31(2):289~293.
[6] Motawi TK, Mahdy SG, Maha M. El-Sawalhi,et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis[J]. Can Physiol Pharmacol,2017,96: 38~44.
[7] Wei Yang, Yun Li, Tian Tian, et al.Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications[J].BMC Endocrine Disorders,2017,17(1):67.
[8] Sakamoto Y, Kameshima S, Kakuda C, et al. Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats[J].Pflugers Arch - Eur Physiol,2017,469:1425~1432.
[9] Kameshima S, Kazama K, Okada M, et al.Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling[J].Am Physiol Heart Circ Physiol,2015, 308(10): H1298~H1305.
[10] Icli A, Cure E, Cure MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus.Angiology[J]. Angiology, 2016, 67(8):749~755.
[11] M. Kose, S. Emet, T.S. Akpinar, et al. Serum endocan level and the severity of coronary artery disease: a pilot study[J].Angiology, 2015,66(8):727~731.
[12] Cimen T, Efe TH, Akyel A, et al.Human Endothelial Cell-Specific Molecule-1 (Endocan) and Coronary Artery Disease and Microvascular Angina[J].Coronary Artery Disease, 2016, 67(9): 846~853.
[13] Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients With Primary Hypertension[J].Angiology, 2017,1:1~7.
[14] Celik T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension:comparative effects of amlodipine and valsartan[J]. Blood Press, 2015, 24(1):55~60.